Biofrontera reports record FY2023 revenue of $34.1M, +19% YoY; Q4 net income $3.5M

Biofrontera Inc.

FY2023 total revenues $34.1M (+19% YoY); operating expenses $56.7M (incl $2M one-time legal).
Q4 2023 revenue $10.6M (+4% YoY); net income $3.5M ($1.65/shr) vs loss $2.8M ($2.16 loss/shr) in Q4 2022.
Adjusted EBITDA for Q4 negative $3.2M (improved from negative $4.4M in prior year).
Submitted sNDA to increase Ameluz use to 3 tubes for AK; PDUFA Oct 4, 2024. Phase 3 enrollment for sBCC completed.
Restructured LSA to cut transfer price to 25% for 2024-2025; acquired patents for new portable PDT lamp.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biofrontera Inc. reported the fourth quarter of 2023 results: revenue $10.6 million, net income $3.5 million, EPS $1.65 per share.

Period: the fourth quarter of 2023
Revenue: $10.6 million
Net income: $3.5 million
EPS: $1.65 per share
Result: reported results

Exact text from the filing

Total revenues for the fourth quarter of 2023 were $10.6 million, an increase of $0.5 million, or ~4%, compared with $10.1 million for the fourth quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biofrontera Inc. reported financial results for the three and twelve months ended December 31, 2023.

Period: the three and twelve months ended December 31, 2023
Result: reported results

Exact text from the filing

On March 15, 2024, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-010152

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.